Xiaonan Z. Hong
270 Dong An Road
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial.
Journal: Blood cancer journal
Published: October 04, 2024
Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study.
Journal: Cancer medicine
Published: February 05, 2024
Predicting central nervous system relapse in primary breast diffuse large B-cell lymphoma using the stage-modified IPI score: A retrospective cohort study.
Journal: Heliyon
Published: August 07, 2023
Efficacy and safety of standard BEACOPP regimen versus ABVD regimen for treatment of advanced Hodgkin's lymphoma.
Journal: Journal of cancer research and therapeutics
Published: March 06, 2023
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: June 17, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Journal: The New England journal of medicine
Published: June 03, 2022
Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma.
Journal: Mediterranean journal of hematology and infectious diseases
Published: May 07, 2022
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.
Journal: Hematological oncology
Published: February 28, 2022
Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.
Journal: Chinese medical journal
Published: February 23, 2022
Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.
Journal: International journal of hematology
Published: January 27, 2022
Prognostic significance of clinical characteristics and 18Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma.
Journal: The Journal of international medical research
Published: January 10, 2022
Last Updated: 09/26/2026